ST Genesia
The ST Genesia is a fully automated commercial analyzer system for performing thrombin generation assays (TGAs) and hence for coagulation testing.[1] It was developed by Diagnostica Stago and was introduced by the company in 2018.[2]
Traditionally, TGAs has been conducted using partially automated methods like the calibrated automated thrombogram (CAT), which was introduced in 2003.[1][3][4] However, the CAT is performed in a 96-well plate and requires specialized technologists to be performed.[1] Consequently, it has seen low implementation in routine laboratories and has been more limited to research settings.[1][5] Lack of standardization with the CAT has also led to difficulties in study-to-study comparisons in research.[1][6] It has been said that the introduction of the ST Genesia system, which will allow TGAs to be performed more easily and also shows improved reproducibility compared to the CAT, should allow for more widespread adoption of TGAs in clinical laboratories.[1][7]
References
- ^ a b c d e f Reda S, Morimont L, Douxfils J, Rühl H (August 2020). "Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests?". Hamostaseologie. 40 (3): 364–378. doi:10.1055/a-1153-5824. PMID 32726831. S2CID 220878363.
- ^ "Stago - Detail - ST Genesia launched!".
- ^ Kintigh J, Monagle P, Ignjatovic V (January 2018). "A review of commercially available thrombin generation assays". Res Pract Thromb Haemost. 2 (1): 42–48. doi:10.1002/rth2.12048. PMC 6055498. PMID 30046705.
- ^ Depasse F, Binder NB, Mueller J, Wissel T, Schwers S, Germer M, Hermes B, Turecek PL (December 2021). "Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine". J Thromb Haemost. 19 (12): 2907–2917. doi:10.1111/jth.15529. PMC 9291770. PMID 34525255. S2CID 237535808.
- ^ Lim HY, Leemaqz SY, Torkamani N, Grossmann M, Zajac JD, Nandurkar H, Ho P, Cheung AS (July 2020). "Global Coagulation Assays in Transgender Women on Oral and Transdermal Estradiol Therapy". J Clin Endocrinol Metab. 105 (7): e2369–e2377. doi:10.1210/clinem/dgaa262. PMID 32413907. S2CID 218659931.
- ^ Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J (2021). "Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk". Front Endocrinol (Lausanne). 12: 769187. doi:10.3389/fendo.2021.769187. PMC 8697849. PMID 34956081.
- ^ Favaloro EJ, Lippi G (April 2019). "Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing". Semin Thromb Hemost. 45 (3): 228–246. doi:10.1055/s-0038-1676579. PMID 30912101. S2CID 85517668.
External links
- ST Genesia launched! - Diagnostica Stago
- v
- t
- e
- Hemoglobin
- Hematocrit
- Red blood cell count
- Red blood cell indices
- Mean corpuscular hemoglobin
- Mean corpuscular hemoglobin concentration
- Mean corpuscular volume
- Red blood cell distribution width
- Red blood cell indices
- White blood cell count
- Platelet count
- Reticulocyte count
- Blood volume
- Total blood volume (TBV)
- Plasma volume (PV)
- Red cell volume (RCV)
- Fetal hemoglobin
- Hemoglobinopathy testing
- Erythrocyte sedimentation rate
- Haptoglobin
- Monocyte distribution width (MDW)
- Osmotic fragility
- Clotting factors
- Bleeding time
- animal enzyme
- Thrombin generation assay
- Calibrated automated thrombogram
- ST Genesia-based test
- Thromboelastography
- Overall hemostatic potential
- Coagulation activation markers
- Fibrinolysis
- Euglobulin lysis time
- D-Dimer
- Plasmin-α2-antiplasmin complex
- Von Willebrand factor
- Ristocetin-induced platelet aggregation
- Activated protein C resistance test
![]() | This medical diagnostic article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e